Due to its unique design, there is no competitor in today’s market with the versatility of the InFlx™ Injector*, nor will there be until 2037.  InFlx's patented technology provides critical advantages over all competitors when a matter of seconds can mean the difference between life and death. This is accomplished using the same injector for Intramuscular, Intranasal, intravenous, and Intraosseous. No other injector on the market today has the capability of converting the same injector for all four applications in a simple low-cost device.

FM has also developed the InFlx II**  Injector, an innovative one-handed dual-chamber injector with a safety shielded needle that can deliver biologics. One chamber of medicament is provided in a lyophilized form and is mixed with a diluent prior to injection to reconstitute the medicament. Storage in the lyophilized form increases the shelf life and efficacy of the medicament in situations such as in third world countries where refrigeration may not be available. 

FM's focus is on the development and manufacturing of a low-cost drug injectable for the civilian emergency market of Epinephrine and Naloxone in the United States and worldwide. FM will then sell these same generic drugs housed in our injector, for the worldwide NATO and civilian emergency medicine markets. Lastly, FM will deliver proprietary pharmaceuticals utilizing our low-cost injectors to the Pharma, Biotech, and Vaccine markets through partnerships.

​

*as described in the international Patent Cooperation Treaty (PCT) patent PCT/US2017/066957 and United States utility patent issued March 19, 2019, (10,232,117)

​

**a unique design as described in the international Patent Cooperation Treaty (PCT) patent PCT/US2019/041100, WO/2020/014292)